Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

32
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
32
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

23
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
23
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

21
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
21
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

45
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
45
Cardiac Catheterization I: Pre-Procedure Overview01:28

Cardiac Catheterization I: Pre-Procedure Overview

153
Cardiac catheterization is an invasive diagnostic technique used to identify and evaluate structural and functional diseases of the heart and major blood vessels. This technique diagnoses congenital heart disease, coronary artery disease, valvular heart disease, and coronary spasms and assesses ventricular function. It helps guide treatment decisions, including the need for revascularization procedures like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and...
153
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

57
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
57

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Sex Differences in Heart Failure Epidemiology and Clinical Characteristics in Spain: A Nationwide Population-Based Study.

Journal of clinical medicine·2026
Same author

Fibrosis Process Activation in Patients with Acute Cardiac Rejection: A Novel Noninvasive Diagnostic Approach.

Biomedicines·2026
Same author

Explaining the Use Behavior of Digital Technologies in Pediatric Rehabilitation: Structural Equation Modeling Analysis of a Cross-Sectional European Survey.

Journal of medical Internet research·2026
Same author

Chloride at the spotlight-but not alone: towards a multi-ionic diuretic strategy.

Clinical kidney journal·2026
Same author

Study protocol for investigating real-world implementation of a combined glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) blood test in the management of adult mild traumatic brain injury in a single-centre European emergency department: the IMPACTS-BRAINI study.

BMJ open·2026
Same author

Achieving High Smoking Abstinence Rates After Myocardial Infarction: A Cardiology-Led Intervention Within Cardiac Rehabilitation.

European journal of preventive cardiology·2026

相关实验视频

Updated: Sep 9, 2025

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.6K

在心力衰竭中对碳水化合物抗原125的评估

Javier de Juan Bagudá1,2,3, Andrea Severo Sánchez4,2, Rafael de la Espriella2,5

  • 1Cardiology. Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Hospital Universitario 12 de Octubre, Madrid, Spain javierdejuan166@hotmail.com.

Heart (British Cardiac Society)
|August 28, 2025
PubMed
概括

在门诊患者中,碳水化合物抗原125 (CA125) 显示出可接受的心力衰竭的诊断性能. 在临床实践中,这种生物标志物可以补充N-终端亲B型尿素 (NT-proBNP).

更多相关视频

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

523
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

213

相关实验视频

Last Updated: Sep 9, 2025

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.6K
Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

523
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

213

科学领域:

  • 心脏病学
  • 生物标志物研究
  • 心脏衰竭的诊断方法

背景情况:

  • 循环碳水化合物抗原125 (CA125) 在心力衰竭 (HF) 风险评估,监测和治疗指导中的作用是公认的.
  • 关于CA125的诊断效果的数据有限,特别是在心力衰竭和保留射出分数 (HFpEF) 中.

研究的目的:

  • 评估CA125在门诊环境中识别HFpEF的诊断性能.
  • 将CA125的诊断准确性与N终端亲B型尿素 (NT-proBNP) 进行比较.

主要方法:

  • 一项前性多中心研究包括246名疑似HF患者.
  • 排除标准包括左心室喷射分数<50%和恶性病史.
  • 最后一组包括210名被盲目的心脏病专家诊断出HFpEF的患者.

主要成果:

  • 研究队列 (n=210) 的平均年龄为69. 7岁,其中69%为女性.
  • 在HFpEF诊断的ROC曲线下,CA125和NT-proBNP显示了可比的区域 (0. 715与0. 765).
  • 最佳切割点是CA125> 12. 2U/ mL (灵敏度为0. 69,特异性为0. 68) 和NT-proBNP> 243pg/ mL (灵敏度为0. 65,特异性为0. 83). 较高的CA125 (> 23U/ ml) 显示高特异性 (0. 97) 和积极的预测值 (80. 8%).

结论:

  • CA125显示出可接受的诊断性能,用于在门诊环境中识别HFpEF.
  • 在临床实践中,CA125可以作为NT-proBNP的宝贵补充生物标志物用于HFpEF诊断.